

Key update to the Buckinghamshire Formulary November 2020

www.bucksformulary.nhs.uk

Amber Protocol

Denosumab 60mg Prolia[®] after stopping or delaying ongoing treatment

In response to the [MHRA Drug Safety Update](#) about an increased risk of multiple, vertebral fractures after stopping or delaying ongoing denosumab 60mg (Prolia[®]), the following is recommended in Bucks:

Do NOT stop or delay denosumab without prior specialist advice. Use 'Advice and Guidance' via ERS:

- at the end of a treatment cycle.
- if there are concerns about serious side effects prior to giving the next injection (mark request as 'urgent').

The Bucks [Denosumab for primary and secondary fracture prevention shared care protocol](#) has been updated to include this advice

Any questions - contact the Medicines Resource Centre by phone, weekdays 9am to 5pm: 01494 425355 or by email bucks.medicinesresourcecentre@nhs.net